U.S. FDA Warning Poses Threat to Dr. Reddy's Revenue Outlook

  • Analysts cut FY17 sales estimate by an average 5 bln rupees
  • Warning increases chance of import alert: Morgan Stanley

Dr. Reddy’s Laboratories Ltd., India’s second-largest drugmaker, could see its sales come under pressure as it faces scrutiny from the U.S. Food and Drug Administration over manufacturing practices at its factories.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.